CareDX Has Reached An Inflection Point, But Regulatory Risks Remain (Upgrade)
Source: SeekingAlpha
2025-12-22 10:15:04 ET
Thesis Update
About a year ago, my first analysis of CareDx, Inc. ( CDNA ) was published. Against the grain of public opinion – almost every other analysis had a Hold or Buy rating – I rating it a “Sell,” due to several concerns I had. These were generally related to the following, which I’ll discuss in more detail later on:
- Profitability.
- Regulatory challenges.
- Competitive moat.
- Litigation issues.
- Management concerns and capital allocation.
Read the full article on Seeking Alpha
For further details see:
CareDX Has Reached An Inflection Point, But Regulatory Risks Remain (Upgrade)
Bio-Rad Laboratories Inc. Class A
NASDAQ: BIO
BIO Trading
11.5% G/L:
$277.42 Last:
471,754 Volume:
$274.72 Open:
BIO Latest News
BIO Stock Data
$8,088,674,023
21,121,296
0.01%
179
N/A
Biotechnology & Life Sciences
Healthcare
US
Hercules
